Business
Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer
Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany– 12 January, 2026 – Boehringer Ingelheim today announced a strategic clinical collaboration with Jazz Pharmaceuticals (Nasdaq: JAZZ) on the exploration of a novel combination therapy for patients with HER2-positive breast cancer. As part of this collaboration, the partners will initiate a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial, evaluating the c
About this update from Jazz Pharmaceuticals Plc
[{"type":"image","alt":"Boehringer Ingelheim Limited","displaySize":"","headline":null,"caption":"Boehringer Ingelheim Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":91,"url":"https://media.zenfs.com/en/globenewswire.com/bef5cffde163baaa9d093287cb47484a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/20MR2y97HE3SX6hXaIlJpw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/bef5cffde163baaa9d093287cb47484a","width":300,"height":91}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients ","length":109,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":109,"olType":false},{"type":"text","content":"Ingelheim, Germany– 12 January, 2026 – Boehringer Ingelheim today announced a strategic clinical collaboration with Jazz Pharmaceuticals (Nasdaq: JAZZ) on the exploration of a novel combination therapy for patients with HER2-positive breast cancer. As part of this collaboration, the partners will initiate a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial, evaluating the combination of Boehringer’s zongertinib and Jazz’s zanidatamab in breast cancer.","length":469,"tagName":"p"},{"type":"text","content":"Despite significant progress in HER2-targeted therapies, HER2-positive breast cancer remains an aggressive subtype, accounting for approximately 15–20% of all breast cancers. Advanced or metastatic patients still have poor five-year survival rates, around 50%. This collaboration aims to improve patient outcomes by combining two differentiated HER2-targeted approaches, potentially offering a new therapeutic option for patients.","length":430,"tagName":"p"},{"type":"text","content":"“At Boehringer Ingelheim, we are committed to pushing the boundaries of science to deliver innovative solutions for patients with high unmet need,” said Itziar Canamasas, Global Head of Oncology at Boehringer Ingelheim. “By combining zongertinib’s precision approach with zanidatamab’s unique bispecific antibody mechanism, we aim to unlock new possibilities for patients living with HER2-expressing breast cancer.”","length":415,"tagName":"p"},{"type":"text","content":"Amal Melhem-Bertrandt, VP, Oncology Therapy Area Head and Zanidatamab Global ...